HIV, Antiretroviral Therapy Exposure Before Birth May Up Obesity Risk in Later Life

Teens and young adults exposed to HIV and antiretroviral treatment while in the womb are at a higher risk of developing obesity later in life, reveals a new study.

Exposure to HIV and antiretroviral treatment before birth may increase the risk of obesity later in life, reports a new study.

Teens and young adults who were exposed to HIV and antiretroviral therapy before birth but are HIV-negative themselves are at increased risk of obesity and asthma-like symptoms, according to research to be presented at ENDO 2019, the Endocrine Society's annual meeting in New Orleans, La.

AIDS and Pregnancy - Treatment - Caring HIV Babies
The Acquired immune deficiency syndrome is brought about by the deadly human immunodeficiency virus. In the USA alone an estimate of 120,000 - 160,000 women are HIV- infected.

‘Exposure to HIV and antiretroviral treatment while in the womb can put you at a higher risk of developing obesity later in life.’
Read More..

"These findings imply that all children of mothers with HIV--even the large proportion who are HIV-negative--should be closely monitored over the life course," said lead researcher Lindsay T. Fourman, M.D., of Massachusetts General Hospital in Boston, Mass.

Worldwide, more than 1 million babies are born to mothers with HIV each year. With the advent of prenatal antiretroviral therapy to prevent maternal transmission of HIV during pregnancy, up to 98 percent of these infants may be HIV-exposed but uninfected (HEU). The long-term consequences of HIV and antiretroviral therapy exposure during pregnancy have not been previously well examined.

The study included 50 HEU adolescents and young adults (13-28 years old) and 141 teens and young adults not exposed to HIV during pregnancy, who were matched for age, sex, race, ethnicity and zip code. The researchers found obesity was present in 42 percent of HEU adolescents and young adults, compared to 25 percent of their non-exposed peers.

Screening for HIV/AIDS Infection
Efficient screening and better drugs help reduce the prevalence of HIV infection. A number of tests like ELIZA & Western Blot are used for screening HIV.

They found the prevalence of reactive airway disease, or having asthma-like symptoms, to be higher in HEU young adults than their non-exposed peers (40 percent vs. 24 percent). The researchers also looked at the mothers' level of immune cells called CD4 cells during the last trimester of pregnancy. Lower prenatal maternal CD4 count is associated with more severe HIV infection during pregnancy.

The study found lower third-trimester CD4 count was strongly associated with increased body mass index (BMI) in HEU adolescents. BMI is a measure of body fat based on height and weight. "This suggests a biologic link between the intrauterine environment in HIV and long-term metabolic outcomes of offspring," Fourman said.

Benefits of Early Antiretroviral Therapy in HIV-infected Children: Study
Initiation of early treatment in HIV-infected infants shows an undeniable clinical benefit by reducing the risk of death in early childhood.

"More broadly, this study adds to growing evidence that the intrauterine environment is an important yet underappreciated determinant of long-term metabolic health. The findings may lead to insights with applications for other groups at increased risk for obesity and metabolic disease, including individuals born to mothers with obesity or diabetes," she said.

"To our knowledge, this study involves the oldest HEU cohort examined to date, and thus provides the most long-term assessment of health complications among this expanding and aging population," Fourman noted.

Immediate Antiretroviral Therapy After HIV Improves Retention Rates
Antiretroviral therapy (ART) immediately after a HIV diagnosis dramatically improves retention in clinical HIV care.

"Our study is also the first to suggest that HEU adolescents and young adults may be at increased risk for obesity and metabolic disease. Additional studies are needed to further determine the unique metabolic risks associated with in utero HIV exposure so that screening, prevention, and treatment measures can be appropriately targeted to this group."

Source-Eurekalert